Find Clinical Trials

Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.

This search will output a list of trials for which you may be eligible based on the criteria you enter.

I want to filter the trials based on location, phase of development, tumor genomic alteration, or drug name, category or target
No preference
No preference
No preference

Matching Trials

For more detailed information please click on the clinical trial number and you will be taken to the clinicaltrials.gov website.
For a key to the icons and text used in the Results column, please click here.
To learn more about our trial annotation process, results assignments, and the criteria used to highlight drugs with promising results, please click here.

  Clinical Trial Phase Eligible Participant Official Title Location Drugs in Trial Results
NCT05445778IIIHigh grade serous FRalpha high+ ovarian cancer with platinum-sensitive recurrence and CR, PR or SD after second line platinum-based therapy, must have avastin with most recent platinum-based therapy (maintenance)Randomized, Multicenter, Open-label, Phase 3 Study of Mirvetuximab Soravtansine in Combination With Bevacizumab Versus Bevacizumab Alone as Maintenance Therapy for Patients With FRα-high Recurrent Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers Who Have Not Progressed After Second Line Platinum-based Chemotherapy Plus Bevacizumab (GLORIOSA)AL, CA, FL, GA, IL, IN, IA, KS, KY, LA, ME, MD, MA, MI, MN, NE, NV, NJ, NY, NC, OH, OK, OR, PA, SD, TN, TX, VAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonistApproved in Ovarian Cancer
Mirvetuximab soravtansineAnti-FOLR1-mab Maytansinoid Conjugate, IMGN853, M9346A-sulfo-SPDB-DM4ADC: anti-FRalpha + microtubule destabilizer (DM4)Approved in Ovarian Cancer
NCT06175221IIaStage I-IV solid tumors (fresh tumor available)A Prospective, Open-Label, All-Comers Phase IIa Trial of The Tumor Lysate, Particle Only (TLPO) Cancer Vaccine in Solid Tumor MalignanciesSCView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
TLPO vaccineImmune response against tumor associated antigensClinical Trials
NCT04804007IIGerm cell tumors after treatment with high-dose chemotherapy (HDCT) and peripheral-blood stem-cell transplant (PBSCT) (maintenance)Randomized Phase 2 Trial of Maintenance Oral Etoposide or Observation Following High-dose Chemotherapy for Relapsed Metastatic Germ-Cell TumorINView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
EtoposideVePesid, Toposar, Lastet, epipodophyllotoxinTopoisomerase II inhibitor
NCT05887609IIHigh grade serous or endometrioid FRalpha medium or high+ ovarian cancer with platinum-sensitive recurrence and CR, PR or SD after most recent platinum-based therapy; BRCA MUT patients must have received prior PARP inhibitor therapy (maintenance)A Phase II Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib in Recurrent Platinum Sensitive Ovarian, Peritoneal, and Fallopian Tube CancerCOView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Mirvetuximab soravtansineAnti-FOLR1-mab Maytansinoid Conjugate, IMGN853, M9346A-sulfo-SPDB-DM4ADC: anti-FRalpha + microtubule destabilizer (DM4)Approved in Ovarian Cancer
OlaparibAZD2281, LynparzaPARP inhibitorApproved in Ovarian Cancer
NCT05726864IAdvanced solid tumors with KRAS G12A/C/D/R/S/V or KRAS G13D or NRAS G12C/D/R/S/V with presence of disease only detectable by circulating cDNA and/or elevated biomarkerFirst in Human Phase 1/2 Trial of ELI-002 7P Immunotherapy as Treatment for Subjects With Kirsten Rat Sarcoma (KRAS)/Neuroblastoma RAS Viral Oncogene Homolog (NRAS) Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid TumorsAZ, CA, CO, FL, IA, MA, MN, NY, PA, TX, WIView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
ELI-002 7PImmune response against cancer expressing KRAS G12A/C/D/R/S/V or KRAS G13D or NRAS G12C/D/R/S/VClinical Trials

If you have any questions or would like help with your search, please call us at: 858-264-6889 or email us at patientsupport@clearityfoundation.org.